FDA approves new treatment option, atezolizumab in combination with chemotherapy, for patients with stage III dMMR colon cancer based on results from the phase III ATOMIC trial led by Alliance. Learn more at https://bit.ly/FDA-ATOMIC #NCI #NCTN #CancerResearch #CRCsm

Dr. Brad McGregor of Dana-Farber leads Alliance A032201 (STRIKE) to see if adding the anti-cancer drug tivozanib to the standard treatment of immunotherapy after surgery helps patients with high-risk renal cell cancer. Learn more: https://bit.ly/Alliance-A032201 #NCI #NCTN #PCSM